New drug combo shows promise in early cancer trial
NCT ID NCT04196530
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if the combination could shrink tumors. Results will help decide if further testing is worthwhile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BDB001 (EIK1001) and atezolizumab (Tecentriq)
What this could lead to
If successful, this could point toward a new combination therapy for advanced solid tumors that have stopped responding to other treatments.
What could go wrong
This is an early Phase 1 trial with only 40 participants, focused on safety and dosing. It is too small and early to know if the combination will work or be safe for broader use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Angeles Clinic
Los Angeles, California, 90025, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34230, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States